Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

Benzinga · 4d ago
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.